Alnylam has evolved into a commercial RNAi leader, with AMVUTTRA powering rapid revenue growth and a strong balance sheet supporting the next leg. The stock earns a Buy as the TTR franchise scales and profitability improves.
Alnylam Pharmaceuticals(ALNY) has moved out of the usual biotech penalty box and into a rarer category: a platform company that has already proven it can turn science into commercial scale. The core investment case rests on three hard facts. First, revenue is now large and accelerating, with 2025 revenue at $3.71B and Q1 2026 revenue at $1.167B, up from $594.2M a year earlier. Second, the flagship TTR franchise is scaling fast, with Q1 2026 global TTR net product revenue of $910M, up 153% YoY, driven by AMVUTTRA’s cardiomyopathy launch. Third, the balance sheet is strong enough to fund the next leg, with $2.91B of cash and equivalents at year-end 2025, $3.009B of cash, cash equivalents and marketable securities at Q1 2026 period end, and net cash of $1.63B against total debt of $1.28B.
That combination matters. Many biotech stories promise platform leverage someday. Alnylam already has six approved medicines, more than 25 clinical programs cited on the Q1 2026 call, and positive GAAP profitability in 2025 with net income of $313.7M. The market is no longer being asked to fund a lab experiment. It is being asked to value a commercial RNAi leader whose growth engine is visible in current numbers and whose pipeline adds optionality on top.
The moderate-risk, medium-term view is constructive but not blind. AMVUTTRA and the broader TTR franchise now carry much of the growth burden, so concentration risk is real. Gross margin also slipped to 80% in Q1 2026 from 85% in Q1 2025 because higher AMVUTTRA sales raised the royalty rate payable to Sanofi. Even so, the operating model is improving faster than the margin headwind is hurting it. Non-GAAP operating income reached $339M in Q1 2026 versus $75M a year earlier, and management reiterated 2026 total net product revenue guidance of $4.9B to $5.3B. In plain English, the machine is scaling, and it is scaling with enough cash and enough product momentum to justify a premium multiple.
Alnylam Pharmaceuticals(ALNY) is a commercial-stage biotechnology company focused on RNA interference, or RNAi, therapeutics. The company was founded in 2002, is headquartered in Cambridge, Massachusetts, and employs 2,500 people. Its business is built around designing small interfering RNA medicines that silence disease-causing messenger RNA before harmful proteins are produced. That upstream mechanism is the company’s defining scientific identity and the basis for its product and pipeline strategy.
The company’s approved product base now includes AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio, and Qfitlia. Some of those assets are commercialized directly and some through partners. The partner list is notable and includes Regeneron, Roche, Sanofi, Novartis, PeptiDream, Dicerna, and Ionis. That collaboration structure gives Alnylam two advantages: it broadens the commercial reach of its science and it adds royalty and collaboration revenue streams on top of direct product sales.
Financially, Alnylam is no longer a small revenue biotech. Core valuation data show market capitalization of $43.19B, trailing P/E of 80.67, forward P/E of 34.13, revenue of $4.29B on a trailing basis, EBITDA of $806.9M, and profit margin of 12.55%. The annual income statement shows a sharp inflection: revenue grew from $844.3M in 2021 to $3.71B in 2025, while operating income moved from a loss of $708.7M in 2021 to positive $501.6M in 2025. That is not a cosmetic improvement. It is a business model transition.
Alnylam’s commercial business is best understood in two buckets: the TTR franchise and the rare disease franchise, with collaboration and royalty revenue as a third supporting stream. The TTR franchise is the main engine. In Q1 2026, global TTR net product revenue reached $910M, up 153% YoY and 6% sequentially. The investor presentation breaks that into a U.S. business that grew 9% QoQ and a rest-of-world business that declined 3% QoQ but still grew 35% YoY.
Within TTR, AMVUTTRA is doing the heavy lifting. The quarterly revenue trend in the investor presentation shows U.S. AMVUTTRA revenue rising from $198M in Q1 2025 to $703M in Q1 2026. Rest-of-world AMVUTTRA revenue rose from $112M to $187M over the same period. ONPATTRO is moving the other way, with U.S. ONPATTRO revenue declining from $16M to $10M and rest-of-world ONPATTRO revenue declining from $34M to $10M. That mix shift is healthy because it shows Alnylam is successfully migrating the franchise toward the newer, more scalable product.
The rare disease franchise remains smaller but steady. Q1 2026 rare net product revenue was $126M, up 15% YoY. The investor presentation notes GIVLAARI grew 11% YoY and OXLUMO grew 22% YoY, with growth driven by a roughly 16% increase in global patients on therapy for GIVLAARI and a roughly 21% increase for OXLUMO. This is not the flashy part of the story, but it matters. It gives Alnylam a second commercial leg and reduces the risk that the company becomes a one-product narrative.
The third stream is collaboration and royalty revenue. In Q1 2026, collaboration revenue was $82.1M and royalty revenue was $49.0M. Royalty revenue rose 85% YoY, driven by higher global Leqvio sales. Collaboration revenue declined 17% YoY because Q1 2025 included a $30M milestone payment from Vir. This is a useful reminder that collaboration revenue can be lumpy, while product revenue is increasingly the cleaner signal for the business.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
AMVUTTRA is the flagship product and the central reason Alnylam’s numbers changed so quickly. It is approved for hereditary transthyretin-mediated amyloidosis with polyneuropathy and, since March 2025 in the U.S., for ATTR amyloidosis with cardiomyopathy to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits. That cardiomyopathy label expansion turned AMVUTTRA from a strong rare-disease asset into a much larger franchise opportunity.
The commercial data back that up. Q1 2026 global TTR revenue was $910M. U.S. TTR revenue grew more than 230% YoY and 9% versus Q4 2025. Management said the $59M U.S. revenue increase over Q4 was achieved despite fewer Q1 shipping weeks and insurance reauthorization dynamics earlier in the year. CFO Jeffrey Poulton added that the quarter was primarily demand driven, with some inventory benefit offset by pricing. That distinction matters because demand growth is more durable than channel noise.
The product’s commercial profile is unusually strong for a specialty launch. Management said access remained broad, pull-through was strong, adherence exceeded 90%, more than 90% of patients had first-line access, and most faced $0 in out-of-pocket costs. The company also reported more than 1,200 unique new U.S. prescribers since the prior March. In biotech, a good drug still needs a functioning distribution and reimbursement machine. AMVUTTRA seems to have both.
The clinical and real-world support also helps. On the Q1 2026 call, management cited real-world data showing greater than 93% adherence to vutrisiran over more than a two-year period and over 85% of patients remaining on therapy for more than a year. The company also referenced HELIOS-B analyses showing vutrisiran reduced the risk of all-cause mortality and cardiovascular events during the double-blind period irrespective of baseline diastolic dysfunction grade. For a chronic cardiology market, adherence and persistence are not side notes. They are revenue durability.
Alnylam’s moat starts with platform leadership. The company’s 10-K describes a delivery stack spanning GalNAc conjugates and lipid nanoparticles for liver delivery, C16-based approaches for CNS and ocular delivery, and active work on heart, skeletal muscle, and adipose delivery. It also describes newer platform layers such as ESC+, IKARIA, and GEMINI. That is the sort of technical depth that makes a platform real rather than a marketing slogan.
Commercial proof is the second moat. By Q1 2026, Alnylam had six invented medicines collectively generating several billion dollars in annual revenue, according to management. Most biotech platforms never get to one approved product, let alone a portfolio. That matters because each approval improves regulatory credibility, manufacturing experience, physician familiarity, and payer comfort with the modality.
The third moat is pipeline breadth with visible late-stage assets. Nucresiran, the next-generation TTR silencer, showed greater than 95% mean TTR knockdown in interim Phase I data and supports a twice-yearly dosing regimen. TRITON-CM enrollment is proceeding faster than expected, and management expanded planned enrollment by about 500 patients, from 1,250 to about 1,750 total. Zilebesiran is already in the Phase III ZENITH cardiovascular outcomes trial for hypertension. Mivelsiran is advancing in cerebral amyloid angiopathy and Alzheimer’s disease. This is a deep bench, not a single backup quarterback.
Alnylam’s operating execution looks stronger than many investors may assume for a fast-scaling biotech. The company has already built the commercial infrastructure required to support AMVUTTRA’s launch in the U.S. and key international markets. Management highlighted a robust provider network, broad access, and favorable reimbursement momentum in Austria, the U.K., Switzerland, and Italy. That is the less glamorous part of biotech, but it is where many launches go to die.
There is also useful detail on U.S. distribution mechanics. CFO Jeffrey Poulton said one wholesale distributor drives about 80% of U.S. volume, ordering every Monday with revenue recognized on Wednesday when inventory is received. Q4 2025 had 14 Wednesdays, while Q1 2026 had 12, which affected quarter-to-quarter comparisons. This is a small but important operational detail because it explains some timing noise without changing the underlying demand trend.
The main operational pressure point is royalties. Gross margin on product sales was 80% in Q1 2026 versus 85% in Q1 2025, and management said the decline was primarily driven by increased royalties on AMVUTTRA payable to Sanofi as sales rose. The royalty rate resets each calendar year and increases as AMVUTTRA sales increase over the course of the year. In other words, success carries a toll. That is manageable, but it does cap some margin expansion.
The most important market for Alnylam is ATTR amyloidosis, especially cardiomyopathy. The 10-K states that ATTR amyloidosis with cardiomyopathy affects more than 300,000 people worldwide, while management said on the Q1 2026 call that ATTR-CM remains significantly underdiagnosed and undertreated, with an estimated 200,000 patients in the U.S. and more than 80% still untreated. That is the kind of market structure growth investors like: a serious disease, low treatment penetration, and a product with growing physician adoption.
The company is trying to expand the market, not just take share inside it. Management said collaborations with Viz.ai and support for an initiative with the American Heart Association are embedding AI diagnostics into real-world care pathways to improve patient identification and accelerate access to therapy. That is strategically smart. In underdiagnosed diseases, market creation can be as valuable as market share.
Outside TTR, the rare disease markets are smaller but still attractive because they support premium pricing and focused commercialization. The 10-K estimates fewer than 30,000 patients worldwide for hATTR amyloidosis with polyneuropathy, about 3,000 diagnosed active AHP patients in the U.S. and EU, and one to three PH1 patients per million in the U.S. and Europe. These are not mass markets, but they are often durable ones when a therapy is effective and first-in-class.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Alnylam’s customer base is layered. The direct prescribers include cardiologists, neurologists, rare disease specialists, and treatment centers managing ATTR, AHP, PH1, and hemophilia-related conditions. For AMVUTTRA in ATTR-CM, the cardiology channel is especially important because that indication expands Alnylam beyond a niche rare-disease footprint into a broader specialist market.
Payers are the second critical customer group. Management said over 90% of patients had first-line access for AMVUTTRA and most faced $0 out-of-pocket costs. That level of reimbursement support is a major commercial asset. It lowers friction at the point of prescribing and helps explain why physician experience with the drug is translating into deeper use over time.
Institutional investors are also a meaningful constituency because biotech valuations can swing on sponsorship quality. Institutional ownership stands at 102.0% of shares outstanding, insider ownership at 0.184%, and short interest at 5.43% of float. Among tracked institutions, 13 increased positions and 7 decreased positions. Capital Research Global Investors increased its holdings by 39.7%, JPMorgan Chase & Co by 34.0%, and T. Rowe Price Investment Management by 78.8%. That is not unanimous enthusiasm, but it is a constructive sponsorship pattern.
Alnylam competes on two levels: modality and indication. On modality, direct RNA-silencing competitors include Arrowhead Pharmaceuticals and Wave Life Sciences, while Ionis is the main antisense competitor. On indication, the most important commercial rival in ATTR is Pfizer’s tafamidis franchise. In hypercholesterolemia, Leqvio competes in a large cardiovascular market but is commercialized by Novartis. In hemophilia and rare disease categories, competition comes from established specialty therapies and pipeline entrants.
Alnylam’s strongest competitive advantage is that it is already commercial at scale. The company is not merely claiming RNAi works. It has six approved medicines and a flagship asset that generated $910M in TTR revenue in Q1 2026. That gives it a credibility edge over earlier-stage RNAi peers. It also gives it a practical edge in manufacturing, regulatory navigation, payer negotiations, and physician education.
The main competitive risk is that TTR is becoming a crowded and strategically important market. Management was asked on the Q1 call about a competitor silencer study, which shows how closely investors are watching the field. That scrutiny is healthy. It means Alnylam’s lead is valuable, but it also means the company must keep proving differentiation through outcomes, dosing convenience, adherence, and prescriber preference. So far, the numbers support that case.
The macro backdrop for Alnylam is better than for a typical development-stage biotech because the company now funds more of its own growth. In 2025, operating cash flow was $524.1M and free cash flow was $465.4M on the annual cash flow statement. That reduces dependence on capital markets, which is a major advantage when rates are higher and biotech financing windows open and shut like a faulty elevator.
Regulatory trends are also supportive. Industry context shows the FDA continues to emphasize rare disease drug development and has issued 2026 guidance aimed at accelerating cell, gene, and RNA-based therapies for ultra-rare diseases. That does not remove clinical risk, but it does support the broader policy environment around the kinds of medicines Alnylam develops.
Geographically, Alnylam’s opportunity is broadening as reimbursement expands. Management cited positive reimbursement and launch milestones for AMVUTTRA in Austria, the U.K., Switzerland, and Italy, while also noting strength in Japan. The main international headwind cited in Q1 2026 was updated pricing in Germany following the ATTR-CM launch. That is a reminder that global biopharma is never just a science story. It is also a pricing and access negotiation, country by country.
$3.009B of cash, cash equivalents and marketable securities at Q1 2026 versus $1.28B of total debt leaves Alnylam with $1.63B of net cash and room to keep funding growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue climbed from $844.3M in 2021 to $3.71B in 2025, while operating income swung from a $708.7M loss to a $501.6M profit.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management reiterated 2026 total net product revenue guidance of $4.9B to $5.3B after Q1 2026 revenue reached $1.167B, up from $594.2M a year earlier.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With a trailing P/E of 80.67 and a forward P/E of 34.13, Alnylam still trades at a premium that depends on AMVUTTRA sustaining its growth rate.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s valuation framework points to $410 as fair value, with upside to $470 and $540 only if growth and execution stay exceptional.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Alnylam Pharmaceuticals(ALNY) has become one of the more interesting large-cap biotech stories because it no longer needs to be sold as a dream. The facts are already substantial: 2025 revenue of $3.71B, Q1 2026 revenue of $1.167B, Q1 2026 product revenue of $1.036B, positive net income in 2025, three consecutive profitable quarters through Q1 2026, and a cash-rich balance sheet.
The bull case is straightforward. AMVUTTRA is winning in a large underdiagnosed market, the TTR franchise is scaling fast, and the RNAi platform continues to produce new shots on goal. The bear case is also straightforward. The stock already carries premium expectations, and a lot depends on sustaining TTR momentum while converting pipeline promise into future products. That tension is exactly why the stock earns a Buy rather than a blanket cheerleading label.
For a moderate-risk investor with a medium-term horizon, Alnylam looks like a high-quality growth biotech with enough commercial proof to justify ownership and enough valuation discipline to demand patience on entry. The fair value estimate is $410. Below that, the risk-reward improves. Well above that, the market starts paying for perfection, and perfection is rarely a good habit in biotech.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Alnylam just got the kind of competitive win biotech investors rarely get handed this cleanly: a rival late-stage ATTR-CM miss after AMVUTTRA already secured the label and commercial traction. With revenue up 65.2% year over year and AMVUTTRA driving more than $1 billion in quarterly product revenue, the stock still looks like the clearest winner in a narrowing field.
Alnylam Pharmaceuticals, Inc. (ALNY) jumps after hours after a rival ATTR-CM therapy suffered a late-stage trial failure, boosting confidence in Alnylam’s approved treatments. Strong Q1 revenue growth, a solid cash position, and improving sentiment add support to the move.
This week’s Q2 earnings recap showed that strong EPS results were not enough to lift every stock. ServiceNow and T-Mobile rallied on beats and upbeat growth stories, while Intel, American Express, and Tesla fell despite key business wins and management optimism.